Injection-associated pain in femoral arteriography: A European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide

Justesen, Per; Downes, Mark; Grynne, B.; Lang, Hanne; Rasch, Wenche; Seim, Eva

doi:10.1007/s002709900147

Cited by 30 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies compared image enhancement of iodixanol with the higher-iodine-concentration agent [4][5][6][7][8]. They reported that iodixanol showed similar enhancement in the aorta and peripheral vessels.…”

mentioning

confidence: 99%

Comparison of iodixanol 320 and iohexol 350 in image quality during 64-slice multidetector computed tomography: Prospective randomized study

Choi¹,

Woo²,

Gupta³

et al. 2012

International Journal of Cardiology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Comparison of iodixanol 320 and iohexol 350 in image quality during 64-slice multidetector computed tomography: Prospective randomized study

Choi¹,

Woo²,

Gupta³

et al. 2012

International Journal of Cardiology

View full text Add to dashboard Cite

“…Finally, osmolarity of intra-arterial contrast media has been shown to affect patient comfort during extremity angiography. 7 For this reason, iso-osmolar contrast is frequently used for upper-and lower-extremity runoff studies.…”

Section: Intravascular Contrast Administrationmentioning

confidence: 99%

Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist

Pasternak

Williamson

2012

Mayo Clinic Proceedings

157

View full text Add to dashboard Cite

Iodinated contrast agents have been in use since the 1950s to facilitate radiographic imaging modalities. Physicians in almost all specialties will either administer these agents or care for patients who have received these drugs. Different iodinated contrast agents vary greatly in their properties, uses, and toxic effects. Therefore, clinicians should be at least superficially familiar with the clinical pharmacology, administration, risks, and adverse effects associated with iodinated contrast agents. This primer offers the non-radiologist physician the opportunity to gain insight into the use of this class of drugs.

show abstract

“…23,24 Several studies that have compared the tolerability of the iso-osmolar contrast medium iodixanol with that of lowosmolar contrast medium report that iso-osmolar contrast medium is associated with a decrease in the intensity of discomfort (heat sensations) and pain. [24][25][26][27][28][29][30] Overall, the key issue that becomes important to define for each specialty is the degree of risk that makes the effort needed to screen patients, identify those at risk, and then implement prevention strategies, a requirement despite any impracticality.…”

Section: The Need For Specialty-specific Guidelinesmentioning

confidence: 99%

Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional Cardiology

Goldfarb

McCullough

McDermott

et al. 2009

Mayo Clinic Proceedings

139

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (AKI) (also known as contrast-induced nephropathy) is an abrupt deterioration in renal function that can be associated with use of iodinated contrast medium. Although the increase in serum creatinine concentration is transient in most cases, contrast-induced AKI may lead to increased morbidity and mortality rates in selected at-risk populations. This review summarizes the findings of a multidisciplinary panel composed of computed tomography radiologists, interventional radiologists, cardiologists, and nephrologists convened to address the specialty-specific issues associated with minimizing the incidence of contrast-induced AKI. As part of this initiative, the panel developed specialty-specific protocols for preventing contrast-induced AKI, taking into account, for example, the variations in patient risk profile, inpatient or outpatient status, and staffing resources that characterize various clinical settings. The 3 protocols, each reflecting a consensus of expert opinion, address the prevention of contrast-induced AKI in interventional radiology, diagnostic computed tomography radiology, and interventional cardiology settings. The protocols are presented in the context of a review of recent guidelines and published reports of trials that discuss contrast-induced AKI and its prevention. © 2009 Mayo Foundation for Medical Education and ResearchA cute kidney injury (AKI) is a heterogeneous disorder with multiple etiologies, risk factors, and clinical presentations. Although patients with AKI are ultimately cared for by nephrologists, AKI occurs in various clinical settings and is associated with a specific etiology in each. The term contrast-induced AKI refers to the disorder as it occurs after exposure to iodinated contrast media, a disorder that has been more commonly known as contrastinduced nephropathy (CIN). The Acute Kidney Injury Network, recognizing the need for improving outcomes associated with the various forms of AKI, recently proposed using the following standardized diagnostic definition in all cases: an abrupt (within 48 hours) reduction in kidney function, evidenced by an increase in the serum creatinine concentration of at least 0.3 mg/dL (to convert to µmol/L, multiply by 88.4) or at least 50% from baseline or a reduction in urine output (documented oliguria of <0.5 mL/kg/h for >6 hours).1,2 The criterion of oliguria does not apply for many cases of contrast-induced AKI because patients are treated with intravenous fluids before and after the procedure with the goal of increasing periprocedural urine output. The most commonly used definition of CIN is an increase from the baseline serum creatinine concentration of at least 0.5 mg/dL or at least 25% within 48 to 72 hours after exposure to contrast media. [3][4][5] Because the medical community is moving to adopt the concept and terminology of the American College of Radiology (ACR) in reference to studies of contrast-induced renal dysfunction and its prevention, 6 this report will do the same. However, we rec...

show abstract

Injection-associated pain in femoral arteriography: A European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide

Abstract: Iodixanol 270 mg I/ml causes significantly less injection-associated pain during femoral arteriography and is as safe and efficacious as iopromide 300 mg I/ml.

Cited by 30 publications

References 15 publications

Comparison of iodixanol 320 and iohexol 350 in image quality during 64-slice multidetector computed tomography: Prospective randomized study

Comparison of iodixanol 320 and iohexol 350 in image quality during 64-slice multidetector computed tomography: Prospective randomized study

Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist

Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional Cardiology

Contact Info

Product

Resources

About